Morgan Stanley
INMB icon

Morgan Stanley’s INmune Bio INMB Stock Holding History

Morgan Stanley’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.4K Sell
8,853
-35,758
-80% -$49.5K ﹤0.01% 6933
2026
Q1 		$50.4K Sell
44,611
-77,901
-64% -$111K ﹤0.01% 6418
2025
Q4 		$191K Buy
122,512
+46,802
+62% +$83.5K ﹤0.01% 5951
2025
Q3 		$157K Sell
75,710
-27,028
-26% -$61.9K ﹤0.01% 5980
2025
Q2 		$237K Buy
102,738
+18,274
+22% +$134K ﹤0.01% 5788
2025
Q1 		$660K Sell
84,464
-70,662
-46% -$561K ﹤0.01% 5205
2024
Q4 		$724K Buy
155,126
+62,982
+68% +$328K ﹤0.01% 5251
2024
Q3 		$497K Buy
92,144
+63,769
+225% +$453K ﹤0.01% 5411
2024
Q2 		$250K Buy
28,375
+896
+3% +$8.83K ﹤0.01% 5582
2024
Q1 		$323K Buy
27,479
+14,676
+115% +$177K ﹤0.01% 5522
2023
Q4 		$144K Buy
12,803
+8,722
+214% +$73.1K ﹤0.01% 5811
2023
Q3 		$27.6K Sell
4,081
-913
-18% -$7.57K ﹤0.01% 6386
2023
Q2 		$45.3K Buy
4,994
+177
+4% +$1.42K ﹤0.01% 6245
2023
Q1 		$31.1K Buy
4,817
+1,829
+61% +$14.7K ﹤0.01% 6458
2022
Q4 		$18.9K Sell
2,988
-126,012
-98% -$894K ﹤0.01% 6712
2022
Q3 		$800K Sell
129,000
-79,282
-38% -$696K ﹤0.01% 5011
2022
Q2 		$1.84M Sell
208,282
-92,199
-31% -$686K ﹤0.01% 4601
2022
Q1 		$2.53M Sell
300,481
-78,006
-21% -$701K ﹤0.01% 4342
2021
Q4 		$3.86M Buy
378,487
+353,856
+1,437% +$5.24M ﹤0.01% 3986
2021
Q3 		$478K Buy
24,631
+13,088
+113% +$253K ﹤0.01% 5524
2021
Q2 		$203K Buy
11,543
+8,450
+273% +$114K ﹤0.01% 6010
2021
Q1 		$37K Buy
3,093
+1,526
+97% +$27.5K ﹤0.01% 6491
2020
Q4 		$27K Buy
1,567
+567
+57% +$5.34K ﹤0.01% 6352
2020
Q3 		$10K Buy
+1,000
New +$10.2K ﹤0.01% 6276

Other funds holding INMB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley's INMB Position: Q2 2026 in Review

Morgan Stanley reduced its INmune Bio (INMB) stake by 80% in Q2 2026, selling an estimated $49.5K and leaving 8,853 shares worth $14.4K. The position accounts for ﹤0.01% of the portfolio, ranked #6933.

Morgan Stanley first reported a position in INMB in Q3 2020 and has held it in 24 quarters since. The position peaked at $3.86M in Q4 2021. 82 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • Morgan Stanley held 8,853 shares of INmune Bio worth $14.4K as of Q2 2026.
  • Morgan Stanley sold 35,758 INmune Bio shares in Q2 2026, an estimated $49.5K.
  • INmune Bio made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6933 holding.
  • Morgan Stanley first reported a position in INmune Bio in Q3 2020 and has held it in 24 quarters since.
  • Morgan Stanley's INmune Bio position peaked at $3.86M in Q4 2021.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.